This inventor holds 8 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Aveo Pharmaceuticals, Inc.. Active years: 2013-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2023
Title: Innovations of Steve Bottega
Introduction
Steve Bottega is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 8 patents to his name, Bottega's work has the potential to impact the treatment of various cell proliferative diseases, including cancer.
Latest Patents
Among his latest patents are the Anti-ErbB3 antibodies. These monoclonal antibodies are designed to bind and inhibit the activation of the epidermal growth factor receptor-related member ErbB3/HER3. The therapeutic applications of these antibodies are particularly relevant for treating certain forms of cancer associated with the activation of ErbB3/HER3.
Career Highlights
Steve Bottega is currently associated with Aveo Pharmaceuticals, Inc., where he continues to innovate in the field of cancer treatment. His expertise in monoclonal antibody development has positioned him as a key figure in the biotechnology sector.
Collaborations
Some of his notable coworkers include Sylvie Vincent and Kristan Meetze, who contribute to the collaborative efforts in research and development at Aveo Pharmaceuticals.
Conclusion
Steve Bottega's work in developing Anti-ErbB3 antibodies showcases his commitment to advancing medical science and improving treatment options for patients with cancer. His contributions to biotechnology are invaluable and continue to pave the way for future innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile